{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:22:26Z","timestamp":1790310146985,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase\u2010related hypersensitivity causes treatment discontinuation, which is associated with decreased event\u2010free survival. To continue asparaginase treatment after hypersensitivity, a formulation of asparaginase encapsulated in erythrocytes (eryaspase) was developed. In NOR\u2010GRASPALL 2016 (NCT03267030) the safety and efficacy of eryaspase was evaluated in 55 patients (aged 1\u201345\u00a0years; median: 6.1\u00a0years) with non\u2010high\u2010risk ALL and hypersensitivity to asparaginase conjugated with polyethylene glycol (PEG\u2010asparaginase). Eryaspase (150\u00a0u\/kg) was scheduled to complete the intended course of asparaginase (1\u20137 doses) in two Nordic\/Baltic treatment protocols. Forty\u2010nine (96.1%) patients had asparaginase enzyme activity (AEA) \u2265100\u00a0iu\/l 14\u00a0\u00b1\u00a02\u00a0days after the first eryaspase infusion [median AEA 511\u00a0iu\/l; interquartile range (IQR), 291\u2013780], whereas six of nine (66.7%) patients had AEA \u2265100\u00a0iu\/l 14\u00a0\u00b1\u00a02\u00a0days after the fourth infusion (median AEA 932\u00a0iu\/l; IQR, 496\u2013163). The mean terminal half\u2010life of eryaspase following the first infusion was 15.3\u00a0\u00b1\u00a015.5\u00a0days. Few asparaginase\u2010related adverse events were reported; five patients (9.1%) developed clinical allergy associated with enzyme inactivation. Replacement therapy was successfully completed in 50 patients (90.9%). Eryaspase was well tolerated, and most patients had AEA levels above the therapeutic target after the first infusion. The half\u2010life of eryaspase confirmed that a 2\u2010week schedule is appropriate.<\/jats:p>","DOI":"10.1111\/bjh.18152","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T15:08:04Z","timestamp":1648480084000},"page":"745-754","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Asparaginase encapsulated in erythrocytes as second\u2010line treatment in hypersensitive patients with acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-5920","authenticated-orcid":false,"given":"Line Stensig","family":"Lynggaard","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Aarhus University Hospital  Aarhus Denmark"},{"name":"Department of Clinical Medicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Vaitkeviciene","sequence":"additional","affiliation":[{"name":"Center of Pediatric Oncology and Hematology Vilnius University Hospital Santaros Klinikos and Vilnius University  Vilnius Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Langenski\u00f6ld","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences Gothenburg University  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Hematology Haukeland Universitetssjukehus  Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi M.","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine Turku University Hospital  Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Lepik","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Tallinn Children's Hospital  Tallinn Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"El Hariry","sequence":"additional","affiliation":[{"name":"Erytech  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet University of Copenhagen  Copenhagen Denmark"},{"name":"Institute of Clinical Medicine, Faculty of Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-3694","authenticated-orcid":false,"given":"Birgitte Klug","family":"Albertsen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Aarhus University Hospital  Aarhus Denmark"},{"name":"Department of Clinical Medicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401310"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"issue":"11","key":"e_1_2_8_4_1","first-page":"878A","article-title":"Therapeutic impact of extended high\u2010dose asparaginase during continuation therapy for standard\u2010risk childhood acute lymphoblastic leukemia. Long term results of the IDH\u2010ALL\u201091 trial of the International BFM Study Group","volume":"102","author":"Arico M","year":"2003","journal-title":"Blood"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10768.1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006583"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15660"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25319"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534347"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02292"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02599-w"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03024"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2070"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24093"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08588.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.06.027"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90133-9"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03148.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12865"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30035-3"},{"key":"e_1_2_8_21_1","unstructured":"WalkerA KR RizzieriD EmadiA KolitzJE StockW ClancyD HokeF YoussoufianH HammA El HariryI LarsonRA eds.A Phase 1 study of eryaspase (L\u2010asparaginase encapsulated in red blood cells) in combination with induction and consolidation chemotherapy for adult patients with newly diagnosed acute lymphoblastic leukemia (ALL)(NCT01910428). American Association for Cancer Research (AACR);2018."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25489"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27458"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137380"},{"key":"e_1_2_8_25_1","first-page":"S43","article-title":"Safety of asparaginase erwinia chrysanthemi (Erwinaze1) in a large compassionate use trial","volume":"60","author":"Plourde P","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.718327"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)80068-5"},{"issue":"24","key":"e_1_2_8_28_1","first-page":"6568","article-title":"Measurement of serum L\u2010asparagine in the presence of L\u2010asparaginase requires the presence of an L\u2010asparaginase inhibitor","volume":"51","author":"Asselin BL","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000030"},{"issue":"1","key":"e_1_2_8_30_1","first-page":"3","article-title":"Quantitative analysis of the relationship between CSF asparagine and whole blood asparaginase in elderly patients with acute lymphocytic leukemia with philadelphia chromosome\u2010negative that received graspa and polychemotherapy","volume":"45","author":"Checchio T","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206433"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04315-0"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18152","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:09:39Z","timestamp":1692846579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/bjh.18152"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18152","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"2022-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}